Kyverna Therapeutics is progressing its drug mivocabtagene autoleucel for autoimmune diseases, targeting approval for stiff person syndrome. Updated trial data show all 26 patients stopped chronic immunotherapies at 16 weeks, with 81% reporting improved mobility, boosting regulatory confidence. The company is submitting a rolling Biologics License Application, aiming for completion by late 2026 and potential approval by mid-2027, with key phase 2/3 data in myasthenia gravis expected soon. Kyverna's cash runway extends into 2028, but a significant equity raise may be needed in 2027 due to a narrow margin before commercialization and a limited initial market size.
Robinhood is expected to see over 20% revenue growth by 2027, driven by a revival in crypto transactions and solid business momentum. The company trades at about 35 times forward free cash flow, with projected free cash flow of $3.1 billion in 2027, ...
Bitcoin's price surged about 37% from around $63,764 on August 3 to a peak near $87,395 by September 21, despite Jim Cramer's public sell call citing quantum computing risks. Cramer sold his entire bitcoin position after an IBM CEO warned quantum thr...
Ventas, a Senior-Care REIT, is rated a buy following four consecutive earnings beats and positive funds from operations trends. Its diverse geographic portfolio and ambitious 2026 investment goals support its growth potential, especially in senior ho...
Trueo, a prediction-market protocol, is migrating its infrastructure from Base, Coinbase's Layer 2 solution, to Ethereum's mainnet to access deeper liquidity, broader integration, and stronger infrastructure. Current markets on Base remain active, bu...
XRP has surged more than 8% in three days following whale accumulation of approximately 1.54 billion tokens valued at $2.2 billion. This buying activity, combined with strong technical support and the upcoming XRP Ledger Batch V1.1 upgrade expected a...
